Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 9/20 | 0.49 |
| ▸ | NPC1 | O15118 | 7/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226336 | 0.84 | MAPT (0.57) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL5100319 | 0.84 | RAB9A (0.56) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL2224879 | 0.84 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL5093936 | 0.84 | GAA (0.59) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL2223579 | 0.83 | LOXL2 (0.58) | ALDH1A1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL2226576 | 0.83 | LOXL2 (0.58) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL5100600 | 0.83 | ABL1 (0.55) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL5101259 | 0.82 | CYP19A1 (0.51) | ALDH1A1MAPTMEN1KMT2AGAA | |
| SCHEMBL17887306 | 0.80 | ALDH1A1 (0.41) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL11569375 | 0.80 | KDM4E (0.63) | ALDH1A1MAPTMEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641887-B | Thiazole derivatives useful as mutant IDH1 inhibitors for the treatment of cancer | 美国政府健康及人类服务部 | 2022-09-20 | — | — | CN | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-107428690-B | Mutant IDH1 inhibitors useful for the treatment of cancer | 美国政府健康及人类服务部 | 2021-04-13 | — | — | CN | disclosed |
| EP-3475276-B1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | US HEALTH (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-3475276-B1 | THIAZOLE DERIVATIVES USEFUL AS MUTANT IDH1 INHIBITORS FOR TREATING CANCER | US HEALTH (US) | 2021-03-31 | — | — | EP | disclosed |
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2020-11-17 | — | — | US | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| US-7465736-B2 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | LABORATOIRES SERONO S.A. (CH) | 2008-12-16 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| US-20060122387-A1 | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells | CTI EUROPE S.R.L. | 2006-06-08 | — | — | US | disclosed |
| EP-1527070-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | Applied Research Systems ARS Holding N.V. (AN) | 2005-05-04 | — | — | EP | disclosed |
| WO-2003105842-A1 | DERIVATIVES OF CHROMEN-2-ONE AS INHIBITORS OF VEGF PRODUCTION IN MAMMALIAN CELLS | NOVUSPHARMA S.P.A. (IT) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106455-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106455-A1 | AZOLE METHYLIDENE CYANIDE DERIVATIVES AND THEIR USE AS PROTEIN KINASE MODULATORS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836759-B2 | Thiazole derivatives useful as mutant IDH1 inhibitors for treating cancer | IDH1, IDH2, IDH3B | ALDH1A1 674/4885MAPT 3875/4885MEN1 21/4885 |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | PRKACA, CSNK1A1, PRKACG | ALDH1A1 3474/4885MAPT 3106/4885MEN1 1553/4885 |
| US-20060122387-A1 | Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells | KDR, FLT1, VEGFA | ALDH1A1 1575/4885MAPT 4137/4885MEN1 2564/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | ALDH1A1 417/4885MAPT 4568/4885MEN1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.